Affibody currently has a pipeline of Affibody® molecules that we intend to develop both as molecular imaging agents and as targeted therapeutics.

The most advanced products in development are targeting proteins which are clinically important in a range of cancer indications such as breast cancer, head and neck cancer and prostate cancer.